Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07730151 Darolutamide Prostatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07730151 clinical trial report covering Darolutamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733115 Iparomlimab/Tuvonralimab Intrahepatic Cholangiocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733115 clinical trial report covering Iparomlimab/Tuvonralimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734415 IMG-007 Eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734415 clinical trial report covering IMG-007, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07732634 Pembrolizumab Head and Neck Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07732634 clinical trial report covering Pembrolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733830 Albumin-Bound Paclitaxel Unresectable Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733830 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600129001 Tislelizumab Metastatic Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
ChiCTR2600129001 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600129028 Atezolizumab Metastatic Carcinoma to the Uterine Cervix Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
ChiCTR2600129028 clinical trial report covering Atezolizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733050 Serplulimab Metastatic Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733050 clinical trial report covering Serplulimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071260068 SFG-02 Urinary Incontinence Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
JPRN-jRCT2071260068 clinical trial report covering SFG-02, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07734012 Mycophenolate Mofetil Scleroderma, Systemic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07734012 clinical trial report covering Mycophenolate Mofetil, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07732491 Culmerciclib Advanced HER2-Positive Breast Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07732491 clinical trial report covering Culmerciclib, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07733466 Cetuximab Squamous cell carcinoma of the oral cavity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
5 August 2026
NCT07733466 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.